

# 1 Methods US Adults Used to Stop Smoking, 2021–2022

2  
3 Floe Foxon<sup>1</sup>, BSc (Hons); Ray Niaura<sup>2</sup>, PhD

4 <sup>1</sup>Department of Data Management and Statistical Analysis, Pinney Associates, Pittsburgh, Pennsylvania

5 <sup>2</sup>Department of Epidemiology, School of Global Public Health, New York University, New York, New York

6 Corresponding Author: Floe Foxon ([ffoxon@pinneyassociates.com](mailto:ffoxon@pinneyassociates.com))

## 7 8 Abstract

9  
10 Nationally representative Centers for Disease Control and Prevention (CDC) survey data  
11 were used to identify which subpopulations of US adults had stopped smoking cigarettes for 6  
12 months or longer in the last year and the methods they used. From 2021 through 2022, 2.9 million  
13 adults stopped smoking. Most of these were male, non-Hispanic White, aged less than 55 years,  
14 college educated, and identified as straight. The most popular method used was nicotine products  
15 (53.9%; 1.5 million adults), especially e-cigarettes in combination with other methods (40.8%; 1.2  
16 million) and e-cigarettes alone (26.0%; 0.7 million). The data suggest that interventions to reduce  
17 smoking could focus on subpopulations that stopped smoking the least and encourage use of  
18 evidence-based methods.

## 20 Introduction

21           Although considerable progress has been made in the last decade in the US to reduce  
22 prevalence of combustible cigarette smoking [1], smoking continues as one of the leading causes of  
23 chronic disease [2]. Thus, further reductions in smoking prevalence are crucial to preventing or  
24 reducing the effects of chronic disease in the US. A previous study identified giving up cigarettes all  
25 at once, gradually cutting back on cigarettes, and substituting some cigarettes with e-cigarettes as  
26 the most commonly reported stop-smoking methods during quit attempts from 2014 through 2016  
27 [3]. More recent data are needed to understand who stopped smoking since 2016 and how they did  
28 it. The objectives of this study were to identify which subpopulations stopped smoking completely  
29 (reported having stopped smoking for  $\geq 6$  months in the past year as defined in previous research  
30 [4]) or tried to stop smoking, and to quantify the methods they used by using the most recent CDC  
31 National Health Interview Survey (NHIS) data [5].

## 32 Methods

33           Data on methods used to stop smoking were sourced from CDC's latest NHIS. These data are  
34 nationally representative and have low bias [5]. The 2022 NHIS (fielded January–December 2022)  
35 asked respondents who had stopped smoking in the past 2 years which methods they used to stop  
36 smoking completely. These analyses focused on those respondents who had stopped smoking in the  
37 last year (2021 through 2022) and who had stopped smoking for 6 months or longer at the time of  
38 the survey. The survey also asked respondents who were still smoking but had tried to stop in the  
39 past year which methods they used when they tried. Full details of questionnaire wording are  
40 available in online supplemental materials (<https://doi.org/10.17605/osf.io/HGMN6>). The  
41 prevalence of each stop-smoking method was calculated with NHIS sampling weights to provide  
42 nationally representative population estimates. NHIS stratum and cluster variables were also used

43 to provide 95% CIs. Demographic characteristics of the sample of adults who stopped smoking or  
44 tried to stop (sex, race or ethnicity, age, education, and sexual orientation) were derived from  
45 standard NHIS questions, similar to other CDC NHIS publications [6, 7].

46 Only publicly available, de-identified survey data were used; therefore, this study is exempt  
47 from NIH human subjects research under NIH exemption 4 and did not require institutional review  
48 board review.

## 49 Results

50 Overall, 2.9 million US adults stopped smoking from 2021 through 2022 and had been  
51 stopped for 6 months or longer at the time of the survey. In the same period, 13.1 million tried to  
52 stop but were unsuccessful. Slightly more men stopped smoking than women (1.6 million vs 1.3  
53 million); most were non-Hispanic White adults, most were aged younger than 55 years, most had at  
54 least some college education, and most self-identified as straight (Table 1). Among those who  
55 stopped smoking for 6 months or longer, the most commonly reported methods used were nicotine  
56 products (53.9%, 1.5 million US adults), primarily e-cigarettes used alone or in combination with  
57 other methods (40.8%, 1.2 million US adults; Table 2). The least commonly reported methods were  
58 non-nicotine, non-prescription drug methods (including a quit line, counseling or clinic, class, or  
59 group) (6.3%, 0.2 million US adults). Of the listed methods, the most commonly reported exclusive  
60 method selected was e-cigarettes; 26.0% (0.7 million US adults) of adults who stopped smoking  
61 from 2021 through 2022 for 6 months or longer selected e-cigarettes as their only listed method.

## 62 Discussion

63 This study identified subpopulations of US adults in NHIS 2022 who stopped or tried to stop  
64 smoking and the methods they used. Results showed that smaller proportions of all adults who

65 stopped smoking from 2021 through 2022 were women, Hispanic and non-Hispanic non-White,  
66 older (aged  $\geq 55$  y), had lower educational attainment (less than some college education), and were  
67 non-heterosexual. This may be explained simply by relative subpopulation size (i.e., the US adult  
68 population comprises fewer non-heterosexual adults compared to heterosexual adults and more  
69 males who smoke than females [8]). Nevertheless, it is important to ensure that specific  
70 subpopulations do not get left behind in efforts to curb smoking.

71       Approximately 40% of adults surveyed in NHIS did not report using any of the surveyed  
72 evidence-based methods to stop smoking. Methods containing nicotine, primarily e-cigarettes, were  
73 the most commonly-reported methods that were explicitly surveyed. This may provide support for  
74 FDA’s “nicotine-focused framework for public health” [9], which describes noncombustible nicotine  
75 products as “a promising foundation for a comprehensive approach to tobacco harm reduction,”  
76 FDA’s efforts to authorize certain e-cigarette products as “appropriate for the protection of public  
77 health” [10], and CDC’s statement that “[e]-cigarettes have the potential to benefit adults who  
78 smoke . . . if used as a complete substitute for regular cigarettes,” [11] while necessarily preventing  
79 access to nicotine products by nonsmoking subpopulations, such as adolescents.

80       This study’s strengths include use of a large, nationally representative survey with low bias  
81 administered by CDC. NHIS results are thought to be generalizable to the entire US population,  
82 because that is the purpose of its sample design by CDC’s National Center for Health Statistics [5,  
83 12]. Another strength is the direct measures of stopping smoking (i.e., survey questions answered  
84 by adults who actually stopped smoking) as opposed to indirect measures of stopping smoking  
85 (e.g., models).

86       This study also has limitations. First is the inability to parse out individual methods in the  
87 “none of the above” category, which is an unavoidable limitation of the NHIS questionnaire design.  
88 Because “none of the above” was inferred from respondents who stopped or tried but who did not

89 select any of the surveyed items, the “none of the above” category may be underrepresented in  
90 these analyses. Furthermore, the questionnaire did not ask respondents about the duration of  
91 treatment use. Future questionnaires should ask respondents for these details. Recall bias may also  
92 limit the accuracy of these findings [13].

93 In conclusion, efforts to reduce smoking among US adults should focus on the  
94 subpopulations that stopped smoking the least and encourage use of evidence-based methods.

## 95 Acknowledgements

96 An early version of this research was presented in poster form at the 2024 Society for  
97 Research on Nicotine and Tobacco (SRNT) annual meeting  
98 (<https://doi.org/10.31219/osf.io/2yuw4>). The authors thank two anonymous reviewers and  
99 participants at the 2024 SRNT meeting for helpful comments and suggestions. This work received  
100 no financial support.

101 The authors declare the following potential conflicts of interests: F.F. provides consulting  
102 services through Pinney Associates on tobacco harm reduction on an exclusive basis to Juul Labs  
103 Inc, which had no involvement in this article. R.N. has received grant and contractual funding from  
104 the National Institutes of Health and the Food and Drug Administration; served as a paid consultant  
105 to the Government of Canada via a contract with Industrial Economics Inc; received an honorarium  
106 for a virtual meeting from Pfizer Inc; received other NIDA grants paid to his employers; received  
107 salary from the Steven Schroeder Institute for Tobacco Research and Policy Studies at The Legacy  
108 Foundation, now Truth Initiative, New York University School of Global Public Health; and  
109 communicated with Juul Labs personnel, for which there was no compensation, and received  
110 hospitality in the form of meals at some meetings; none of which supported the work reported here.

## 111 References

- 112
- 113 1. Levy DT, Sánchez-Romero LM, Travis N, Yuan Z, Li Y, Skolnick S, et al. US nicotine vaping product  
114 Simsmoke simulation model: the effect of vaping and tobacco control policies on smoking  
115 prevalence and smoking-attributable deaths. *Int J Environ Res Public Health*. 2021;18(9):4876.  
116 PubMed <https://doi.org/10.3390/ijerph18094876>
- 117 2. Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. GBD 2019 Risk  
118 Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019:  
119 a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1223–  
120 1249. PubMed [https://doi.org/10.1016/S0140-6736\(20\)30752-2](https://doi.org/10.1016/S0140-6736(20)30752-2)
- 121 3. Caraballo RS, Shafer PR, Patel D, Davis KC, McAfee TA. Quit methods used by US adult cigarette  
122 smokers, 2014–2016. *Prev Chronic Dis*. 2017;14:E32. PubMed  
123 <https://doi.org/10.5888/pcd14.160600>
- 124 4. Walton K, Wang TW, Prutzman Y, Jamal A, Babb SD. Characteristics and correlates of recent  
125 successful cessation among adult cigarette smokers, United States, 2018. *Prev Chronic Dis*.  
126 2020;17:E154. PubMed <http://dx.doi.org/10.5888/pcd17.200173>
- 127 5. Zablotsky B, Lessem SE, Gindi RM, Maitland AK, Dahlhamer JM, Blumberg SJ. Overview of the  
128 2019 National Health Interview Survey questionnaire redesign. *Am J Public Health*.  
129 2023;113(4):408–415. PubMed <https://doi.org/10.2105/AJPH.2022.307197>
- 130 6. Cornelius ME, Wang TW, Jamal A, Loretan CG, Neff LJ. Tobacco product use among adults —  
131 United States, 2019. *MMWR Morb Mortal Wkly Rep*. 2020;69(46):1736–1742. PubMed  
132 <https://doi.org/10.15585/mmwr.mm6946a4>
- 133 7. Cornelius ME, Loretan CG, Wang TW, Jamal A, Homa DM. Tobacco product use among adults —  
134 United States, 2020. *MMWR Morb Mortal Wkly Rep*. 2022;71(11):397–405. PubMed  
135 <https://doi.org/10.15585/mmwr.mm7111a1>
- 136 8. Cornelius ME, Loretan CG, Jamal A, Davis Lynn BC, Mayer M, Alcantara IC, et al. Tobacco product  
137 use among adults — United States, 2021. *MMWR Morb Mortal Wkly Rep*. 2023;72(18):475–483.  
138 PubMed <https://doi.org/10.15585/mmwr.mm7218a1>
- 139 9. Gottlieb S, Zeller M. A nicotine-focused framework for public health. *N Engl J Med*.  
140 2017;377(12):1111–1114. PubMed <https://doi.org/10.1056/NEJMp1707409>

- 141 10. US Food and Drug Administration. Premarket tobacco product marketing granted orders.  
142 Accessed January 26, 2024. [https://www.fda.gov/tobacco-products/premarket-tobacco-product-](https://www.fda.gov/tobacco-products/premarket-tobacco-product-applications/premarket-tobacco-product-marketing-granted-orders)  
143 [applications/premarket-tobacco-product-marketing-granted-orders](https://www.fda.gov/tobacco-products/premarket-tobacco-product-marketing-granted-orders)
- 144 11. Centers for Disease Control and Prevention. About electronic cigarettes (e-cigarettes). Accessed  
145 January 26, 2024.  
146 [https://web.archive.org/web/20240102195530/https://www.cdc.gov/tobacco/basic information](https://web.archive.org/web/20240102195530/https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html)  
147 [/e-cigarettes/about-e-cigarettes.html](https://web.archive.org/web/20240102195530/https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html)
- 148 12. Centers for Disease Control and Prevention; US Department of Health and Human Services,  
149 Division of Health Interview Statistics, National Center for Health Statistics. National Health  
150 Interview Survey 2022 survey description. Published 2023. Accessed January 26, 2024.  
151 [https://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Dataset\\_Documentation/NHIS/2022/srvydesc-](https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2022/srvydesc-508.pdf)  
152 [508.pdf](https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2022/srvydesc-508.pdf)
- 153 13. Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies  
154 may underestimate the effectiveness of stop-smoking medications. *Nicotine Tob Res.*  
155 2012;14(12):1483–1487. PubMed <https://doi.org/10.1093/ntr/nts002>
- 156

157 Table 1. Demographic Characteristics of Adults Who Stopped Smoking (N =  
 158 304), or Tried to Stop Smoking but Did Not Stop Smoking from 2021 through  
 159 2022 (N = 1,431), National Health Interview Survey 2021–2022<sup>a</sup>  
 160

Characteristic	Stopped smoking completely <sup>b</sup> , weighted % (95% CI) (weighted N, millions)	Tried to stop smoking but did not stop smoking, weighted % (95% CI) (weighted N, millions)
All adults	100 (2.9)	100 (13.1)
Sex		
Female	45.3 (39.3–51.4) (1.3)	44.2 (41.1–47.2) (5.8)
Male	54.7 (48.6–60.7) (1.6)	55.8 (52.8–58.9) (7.3)
Race or ethnicity		
Hispanic	15.2 (10.8–20.6) (0.4)	12.0 (9.9–14.4) (1.6)
Non-Hispanic Black	11.2 (7.5–15.9) (0.3)	16.1 (13.7–18.6) (2.1)
Non-Hispanic White	67.3 (60.8–73.2) (1.9)	65.1 (62.1–68.0) (8.5)
Non-Hispanic Other	6.3 (3.5–10.3) (0.2)	6.8 (5.4–8.6) (0.9)
Age, y		
18–34	41.9 (35.4–48.7) (1.2)	24.7 (21.9–27.6) (3.2)
35–54	34.2 (27.9–40.9) (1.0)	39.6 (36.4–42.8) (5.2)
55 or older	23.9 (19.0–29.3) (0.7)	35.7 (33.0–38.6) (4.7)
Education		
≤12 years (no diploma)	9.4 (5.8–14.2) (0.3)	18.5 (16.0–21.3) (2.4)
GED certificate or high school diploma	34.4 (28.7–40.5) (1.0)	38.5 (35.5–41.7) (5.0)
Some college (no degree)	18.8 (14.4–23.9) (0.5)	17.1 (15.1–19.3) (2.2)
Associate, undergraduate, or graduate degree	37.3 (31.3–43.8) (1.1)	25.8 (23.2–28.5) (3.4)
Sexual orientation		
Gay/lesbian/bisexual	12.8 (8.6–18.0) (0.4)	5.8 (4.5–7.4) (0.8)
Straight	82.8 (76.7–87.9) (2.4)	90.0 (88.1–91.7) (11.8)
Other	4.4 (1.8–8.8) (0.1)	4.1 (3.0–5.6) (0.5)

161  
 162 <sup>a</sup> Following Cornelius et al [8], modified Clopper-Pearson confidence limits were calculated by using the Korn  
 163 and Graubard method.

164 <sup>b</sup> Reported having stopped smoking for 6 months or longer in the past year, as defined in previous research  
 165 [4].

166



167 Table 2. Methods Used by Adults Who Stopped Smoking (N = 304), or Tried to  
 168 Stop Smoking but Did Not Stop Smoking (N = 1,431), National Health  
 169 Interview Survey, 2021–2022<sup>a</sup>  
 170

Method(s)	Stopped smoking completely <sup>b</sup> , weighted % (95% CI) (weighted N, millions)	Tried to stop smoking but did not stop smoking, weighted % (95% CI) (weighted N, millions)
Any method	100 (2.9)	100 (13.1)
Nicotine products		
E-cigarettes	40.8 (34.4–47.5) (1.2)	20.7 (18.1–23.4) (2.7)
Exclusively <sup>c</sup>	26.0 (20.6–32.0) (0.7)	11.2 (9.3–13.3) (1.5)
Nicotine gum/lozenge	18.8 (14.1–24.4) (0.5)	19.0 (16.7–21.4) (2.5)
Exclusively <sup>c</sup>	— <sup>d</sup>	4.8 (3.7–6.2) (0.6)
Nicotine patch	15.4 (11.1–20.6) (0.4)	22.1 (19.7–24.6) (2.9)
Exclusively <sup>c</sup>	5.4 (2.8–9.5) (0.2)	7.4 (6.1–9.0) (1.0)
Nicotine nasal spray/inhaler	— <sup>d</sup>	0.9 (0.5–1.7) (0.1)
Exclusively <sup>c</sup>	— <sup>d</sup>	— <sup>d</sup>
One or more of the above	53.9 (47.4–60.3) (1.5)	45.1 (42.0–48.2) (5.9)
Prescription drug products		
Varenicline	5.1 (2.9–8.2) (0.1)	11.3 (9.5–13.3) (1.5)
Exclusively <sup>c</sup>	— <sup>d</sup>	3.0 (2.1–4.2) (0.4)
Bupropion	4.7 (2.6–7.7) (0.1)	7.4 (5.9–9.0) (1.0)
Exclusively <sup>c</sup>	— <sup>d</sup>	1.7 (1.0–2.7) (0.2)
One or more of the above	8.1 (5.3–11.8) (0.2)	16.2 (14.2–18.5) (2.1)
One or more pharmacotherapy (nicotine product incl. e- cigarettes or prescription drug product)	56.6 (49.9–63.1) (1.6)	51.1 (47.9–54.3) (6.7)
Non-nicotine, non-prescription drug methods		
Quit line	3.1 (1.4–5.7) (0.1)	4.3 (3.2–5.7) (0.6)
Exclusively <sup>c</sup>	3.1 (1.4–5.7) (0.1)	— <sup>d</sup>
Counseling	3.1 (1.5–5.7) (0.1)	4.8 (3.6–6.2) (0.6)
Exclusively <sup>c</sup>	— <sup>d</sup>	0.6 (0.3–1.2) (0.1)
Clinic/class/group	— <sup>d</sup>	2.5 (1.7–3.5) (0.3)
Exclusively <sup>c</sup>	— <sup>d</sup>	— <sup>d</sup>
One or more of the above	6.3 (3.9–9.7) (0.2)	7.9 (6.4–9.7) (1.0)
Any of the above <sup>e</sup>	57.5 (50.8–63.9) (1.6)	52.5 (49.2–55.7) (6.9)
None of the above <sup>f</sup>	42.5 (36.1–49.2) (1.2)	47.5 (44.3–50.8) (6.2)

171  
 172 <sup>a</sup> Following Cornelius et al [8], modified Clopper-Pearson confidence limits were calculated by using the Korn  
 173 and Graubard method.

174 <sup>b</sup> Reported having stopped smoking for 6 months or longer in the past year, as defined in previous research  
 175 [4].

176 <sup>c</sup> Exclusive percentages are expressed among all adults who stopped or tried to stop smoking, not as a  
 177 percentage of those adults who used the particular method (e.g., 26.0% of all adults who stopped smoking  
 178 used e-cigarettes exclusively). Exclusive means the respondent selected that particular method but did not  
 179 select the other methods listed on the questionnaire (e.g., exclusive e-cigarette means reported using e-  
 180 cigarettes but not nicotine gum or lozenge, nicotine patch, nicotine, nasal spray/inhaler, varenicline,  
 181 bupropion, a quit line, or counseling).

182 <sup>d</sup> Estimates with an unweighted denominator or numerator less than 10, relative 95% CI width >160%, or  
183 degrees of freedom less than 8 are suppressed, consistent with the latest 2023 National Center for Health  
184 Statistics standards for rates and counts ([https://www.cdc.gov/nchs/data/series/sr\\_02/sr02-200.pdf](https://www.cdc.gov/nchs/data/series/sr_02/sr02-200.pdf)).

185 <sup>e</sup> Stopped smoking “completely” from 2021 through 2022 or tried from 2021 through 2022 and reported  
186 using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline,  
187 bupropion, quit line, counseling, or clinic/class/group.

188 <sup>f</sup> Stopped smoking “completely” from 2021 through 2022 or tried from 2021 through 2022 but did not report  
189 using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline,  
190 bupropion, quit line, counseling, or clinic/class/group.